Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients

Introduction Cetuximab is registered for use in colorectal cancer (CRC) patients with RAS wild-type tumours only. Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification (prenylation) of KRAS. We hypothesize that the activitated KRAS pathway in KRAS...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Baas, J. M., Krens, L. L., ten Tije, A. J., Erdkamp, F., van Wezel, T., Morreau, H., Gelderblom, H., Guchelaar, H. J.
Format: Artigo
Langue:Inglês
Publié: Springer US 2015
Sujets:
Phase II Studies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648966/
https://ncbi.nlm.nih.gov/pubmed/26386973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0285-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires